Previous close | 136.70 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | 1.27 |
PE ratio (TTM) | 0.69 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NEW YORK, July 09, 2024--IFF (NYSE:IFF) today announced that it will release its second quarter 2024 earnings results following the market close on Tuesday, August 6, 2024. The management team will host a live webcast on Wednesday, August 7, 2024 at 9:00 a.m. ET to discuss results and outlook with the investor community.
IFF today announced EU-wide regulatory approval for two of its groundbreaking feed solutions for poultry. Axtra® XAP – a multi-enzyme blend and Syncra® AVI – an enzyme-probiotic complex from Danisco Animal Nutrition & Health, IFF's Health & Biosciences business unit, are formulated to meet the challenges of modern poultry production and deliver measurable performance improvements.
NEW YORK, May 30, 2024--IFF (NYSE: IFF) today announced the appointment of Margarita Paláu-Hernández to its Board of Directors, effective June 3, 2024. Paláu-Hernández joins as a mutually agreed independent Director in connection with IFF’s previously disclosed cooperation agreement with Icahn Capital LP and its affiliates. Following the appointment of Paláu-Hernández, the Board will be comprised of 11 members, ten of which are independent.